Trial in Progress: Isatuximab and Iberdomide as Immunotherapy for High-Risk Smouldering Myeloma - the UK Myeloma Research Alliance MODIFY Clinical Trial (IMS 2026) - Sep 11, 2026 - Abstract #PA-509; Pres time: Sep 23, 2026; "Patients receive isatuximab (1400 mg subcutaneous), iberdomide (Cereblon E3 ligase modulator, 1.0 mg) and dexamethasone (20 mg) for a fixed duration of 2 years (26 cycles). n/a"
Clinical • Hematological Malignancies • Multiple Myeloma • Targeted Protein Degradation • CRBN
|
|
Dean Smith1; Simon Hallam2; Ceri Bygrave3; Kamaraj Karunanithi4; Martin Kaiser5; Catherine S. Y. Lecat6; Sally Jeans, Adelle Martin, Ruth De Tute7; Rachel Chadband7; Adefiola Olabode8; Charlotte Tyson8; William Wilson8; Karthik Ramasamy9; Kwee Yong10
|